Technical Analysis for BMEA - Biomea Fusion, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 15.77 | -11.68% | -2.09 |
BMEA closed down 11.68 percent on Monday, March 18, 2024, on 1.47 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 0.00% | |
Fell Below 200 DMA | Bearish | 0.00% | |
Fell Below 50 DMA | Bearish | 0.00% | |
MACD Bearish Signal Line Cross | Bearish | 0.00% | |
20 DMA Support | Bullish | -11.68% | |
50 DMA Support | Bullish | -11.68% | |
Crossed Above 200 DMA | Bullish | -11.68% | |
MACD Bullish Signal Line Cross | Bullish | -11.68% | |
Pocket Pivot | Bullish Swing Setup | -11.68% | |
Volume Surge | Other | -11.68% |
Alert | Time |
---|---|
Down 10% | about 15 hours ago |
60 Minute Opening Range Breakdown | about 16 hours ago |
Fell Below 10 DMA | about 16 hours ago |
Down 1 ATR | about 16 hours ago |
20 DMA Support | about 17 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/26/2024
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
T
TraderMike 12 months ago
I found this on the "Calm After Storm" scan today (I also like the NR7 & Doji). These little biotechs are always interesting after having a big pop based on some good/promising news. The standard plan seems to be to immediately issue a secondary offering -- which BMEA did. So now I'm looking for it to climb back above that offering price of $30 and retest the March high.
View full discussion...
Indicator | Value |
---|---|
52 Week High | 43.64 |
52 Week Low | 8.125 |
Average Volume | 997,964 |
200-Day Moving Average | 17.45 |
50-Day Moving Average | 16.70 |
20-Day Moving Average | 16.76 |
10-Day Moving Average | 16.35 |
Average True Range | 1.53 |
RSI (14) | 45.36 |
ADX | 17.45 |
+DI | 21.17 |
-DI | 22.30 |
Chandelier Exit (Long, 3 ATRs) | 14.75 |
Chandelier Exit (Short, 3 ATRs) | 18.84 |
Upper Bollinger Bands | 18.92 |
Lower Bollinger Band | 14.61 |
Percent B (%b) | 0.27 |
BandWidth | 25.72 |
MACD Line | -0.11 |
MACD Signal Line | -0.05 |
MACD Histogram | -0.0577 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 18.96 | ||||
Resistance 3 (R3) | 19.31 | 18.60 | 18.43 | ||
Resistance 2 (R2) | 18.60 | 17.79 | 18.43 | 18.25 | |
Resistance 1 (R1) | 17.18 | 17.29 | 16.83 | 16.83 | 18.07 |
Pivot Point | 16.47 | 16.47 | 16.29 | 16.30 | 16.47 |
Support 1 (S1) | 15.05 | 15.66 | 14.70 | 14.70 | 13.46 |
Support 2 (S2) | 14.34 | 15.16 | 14.17 | 13.28 | |
Support 3 (S3) | 12.92 | 14.34 | 13.10 | ||
Support 4 (S4) | 12.57 |